Journal
DRUGS OF TODAY
Volume 45, Issue 10, Pages 725-730Publisher
PROUS SCIENCE, SA-THOMSON REUTERS
DOI: 10.1358/dot.2009.45.10.1417873
Keywords
-
Categories
Ask authors/readers for more resources
Pharmacological methods of achieving androgen deprivation for the treatment of prostate cancer hove evolved. New strategies ore focusing on avoidance of the undesirable effects of testosterone surges or flares associated with the initial stages of gonadotropin-releasing hormone (GnRH) agonists and the significant histamine-mediated side effects that can be associated with GnRH antagonists. Degarelix acetate (Firmagon (R); Ferring Pharmaceuticals) is a third-generation GnRH antagonist that has been shown to produce a significantly more rapid medical castration (without testosterone surge) and prostate-specific antigen response compared with GnRH agonists. The safety profile is comparable to GnRH agonists and anaphylactic reactions have not been reported. Degarelix is currently available as a 1-month subcutaneous injection and has been approved for the treatment of advanced prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available